Literature DB >> 25357113

Estrogen receptor expression is high but is of lower intensity in tubular carcinoma than in well-differentiated invasive ductal carcinoma.

Julie M Jorns1, Dafydd G Thomas, Patrick N Healy, Stephanie Daignault, Tammi L Vickery, Jacqueline E Snider, Elaine R Mardis, Sherri R Davies, Matthew J Ellis, Daniel W Visscher.   

Abstract

CONTEXT: Tubular carcinoma (TC) is a rare, luminal A subtype of breast carcinoma with excellent prognosis, for which adjuvant chemotherapy is usually contraindicated.
OBJECTIVE: To examine the levels of estrogen receptor (ER) and progesterone receptor expression in cases of TC and well-differentiated invasive ductal carcinoma as compared to normal breast glands and to determine if any significant differences could be detected via molecular testing.
DESIGN: We examined ER and progesterone receptor via immunohistochemistry in tubular (N = 27), mixed ductal/tubular (N = 16), and well-differentiated ductal (N = 27) carcinomas with comparison to surrounding normal breast tissue. We additionally performed molecular subtyping of 10 TCs and 10 ductal carcinomas via the PAM50 assay.
RESULTS: Although ER expression was high for all groups, TC had statistically significantly lower ER staining percentage (ER%) (P = .003) and difference in ER expression between tumor and accompanying normal tissue (P = .02) than well-differentiated ductal carcinomas, with mixed ductal/tubular carcinomas falling between these 2 groups. Mean ER% was 79%, 87%, and 94%, and mean tumor-normal ER% differences were 13.6%, 25.9%, and 32.6% in tubular, mixed, and ductal carcinomas, respectively. Most tumors that had molecular subtyping were luminal A (9 of 10 tubular and 8 of 10 ductal), and no significant differences in specific gene expression between the 2 groups were identified.
CONCLUSIONS: Tubular carcinoma exhibited decreased intensity in ER expression, closer to that of normal breast parenchyma, likely as a consequence of a high degree of differentiation. Lower ER% expression by TC may represent a potential pitfall when performing commercially available breast carcinoma prognostic assays that rely heavily on ER-related gene expression.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25357113      PMCID: PMC4327939          DOI: 10.5858/arpa.2013-0621-OA

Source DB:  PubMed          Journal:  Arch Pathol Lab Med        ISSN: 0003-9985            Impact factor:   5.534


  22 in total

1.  Tubular carcinoma and grade 1 (well-differentiated) invasive ductal carcinoma: comparison of flat epithelial atypia and other intra-epithelial lesions.

Authors:  Lakshmi P Kunju; Ying Ding; Celina G Kleer
Journal:  Pathol Int       Date:  2008-10       Impact factor: 2.534

2.  A long-term follow-up study of survival in stage I (T1N0M0) and stage II (T1N1M0) breast carcinoma.

Authors:  P R Rosen; S Groshen; P E Saigo; D W Kinne; S Hellman
Journal:  J Clin Oncol       Date:  1989-03       Impact factor: 44.544

Review 3.  The role of molecular analysis in breast cancer.

Authors:  Felipe C Geyer; Caterina Marchio; Jorge S Reis-Filho
Journal:  Pathology       Date:  2009-01       Impact factor: 5.306

4.  Analytical validation of the Oncotype DX genomic diagnostic test for recurrence prognosis and therapeutic response prediction in node-negative, estrogen receptor-positive breast cancer.

Authors:  Maureen Cronin; Chithra Sangli; Mei-Lan Liu; Mylan Pho; Debjani Dutta; Anhthu Nguyen; Jennie Jeong; Jenny Wu; Kim Clark Langone; Drew Watson
Journal:  Clin Chem       Date:  2007-04-26       Impact factor: 8.327

5.  Supervised risk predictor of breast cancer based on intrinsic subtypes.

Authors:  Joel S Parker; Michael Mullins; Maggie C U Cheang; Samuel Leung; David Voduc; Tammi Vickery; Sherri Davies; Christiane Fauron; Xiaping He; Zhiyuan Hu; John F Quackenbush; Inge J Stijleman; Juan Palazzo; J S Marron; Andrew B Nobel; Elaine Mardis; Torsten O Nielsen; Matthew J Ellis; Charles M Perou; Philip S Bernard
Journal:  J Clin Oncol       Date:  2009-02-09       Impact factor: 44.544

6.  Invasive tubular carcinoma of the breast frequently is clonally related to flat epithelial atypia and low-grade ductal carcinoma in situ.

Authors:  Sebastian Aulmann; Zeinab Elsawaf; Roland Penzel; Peter Schirmacher; Hans Peter Sinn
Journal:  Am J Surg Pathol       Date:  2009-11       Impact factor: 6.394

7.  Prognostic value of a combined estrogen receptor, progesterone receptor, Ki-67, and human epidermal growth factor receptor 2 immunohistochemical score and comparison with the Genomic Health recurrence score in early breast cancer.

Authors:  Jack Cuzick; Mitch Dowsett; Silvia Pineda; Christopher Wale; Janine Salter; Emma Quinn; Lila Zabaglo; Elizabeth Mallon; Andrew R Green; Ian O Ellis; Anthony Howell; Aman U Buzdar; John F Forbes
Journal:  J Clin Oncol       Date:  2011-10-11       Impact factor: 44.544

8.  Predictive algorithms for adjuvant therapy: TransATAC.

Authors:  Mitch Dowsett; Janine Salter; Lila Zabaglo; Elizabeth Mallon; Antony Howell; Aman U Buzdar; John Forbes; S Pineda; Jack Cuzick
Journal:  Steroids       Date:  2011-04-04       Impact factor: 2.668

9.  Transcriptomic analysis of tubular carcinomas of the breast reveals similarities and differences with molecular subtype-matched ductal and lobular carcinomas.

Authors:  Maria A Lopez-Garcia; Felipe C Geyer; Rachael Natrajan; Bas Kreike; Alan Mackay; Anita Grigoriadis; Jorge S Reis-Filho; Britta Weigelt
Journal:  J Pathol       Date:  2010-09       Impact factor: 7.996

10.  Comparison of PAM50 risk of recurrence score with oncotype DX and IHC4 for predicting risk of distant recurrence after endocrine therapy.

Authors:  Mitch Dowsett; Ivana Sestak; Elena Lopez-Knowles; Kalvinder Sidhu; Anita K Dunbier; J Wayne Cowens; Sean Ferree; James Storhoff; Carl Schaper; Jack Cuzick
Journal:  J Clin Oncol       Date:  2013-07-01       Impact factor: 44.544

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.